Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02129725 · ClinicalTrials.gov registry record · Phase 4
Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT02129725 is a Phase 4 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT02129725, a Phase 4 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Our research proposal will determine if PDE-5 inhibition exerts a favorable effect on insulin signaling pathways in skeletal muscle of subjects with impaired fasting glucose and/or impaired glucose tolerance.
Interventions
- DRUG Placebo Oral Capsule
- DRUG Sildenafil citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02129725
The ClinicalTrials.gov registry entry for NCT02129725 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT02129725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02129725 about?
NCT02129725 is a clinical study titled "Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.". Our research proposal will determine if PDE-5 inhibition exerts a favorable effect on insulin signaling pathways in skeletal muscle of subjects with impaired fasting glucose and/or impaired glucose tolerance.
What is the current status of trial NCT02129725?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2014-04. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02129725?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Sildenafil citrate (DRUG).
Who is sponsoring clinical trial NCT02129725?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.